Seminars in Hematology
Volume 37, Issue 3 , Pages 229-238 , July 2000

Can drugs cause autoimmune thrombocytopenic purpura?

  • Richard H Aster

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Richard H. Aster, MD, Blood Research Institute, The Blood Center of Southeastern Wisconsin, PO Box 2178, Milwaukee, WI 53201-2178.
    • From the the Blood Research Institute, The Blood Center of Southeastern Wisconsin USA
    • From the Departments of Medicine and Pathology, Medical College of Wisconsin, Milwaukee, WI, USA

References 

  1. Ackroyd JF. The role of Sedormid in the immunological reaction that results in platelet lysis in Sedormid purpura. Clin Sci. 1954;13:409–423
  2. Adachi JD, Bansen WG, Kassam Y, et al.  Gold-induced thrombocytopenia: 12 cases and a review of the literature. In: ed 9. Semin Arthritis Rheum. 16:1987;p. 287–293
  3. Aster RH. Response of thrombocytes to toxic injury. In: ed 9.  Bloom JC editors. Comprehensive Toxicology. vol 4:Amsterdam, the Netherlands: Elsevier Science; 1997;p. 263–284
  4. Aster RH. Drug-induced immune thrombocytopenia: An overview of pathogenesis. In: ed 9. Semin Hematol. 36:1999;p. 2–6 (suppl 1)
  5. Barnaba V. Viruses: Hidden self-epitopes and autoimmunity. Immunol Rev. 1996;152:47–66
  6. Beaune PH, LeCoueur S, Bourdi M, et al.  Anti-cytochrome P450 autoantibodies in drug-induced disease. Eur J Haematol. 1996;57:89–92 (suppl)
  7. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics—The dynamics of drug absorption, distribution, and elimination. In:  Hardman JG,  Limbird LE,  Molinoff PB, et al. editor. The Pharmacological Basis of Therapeutics. ed 9. New York, NY: McGraw-Hill; 1996;p. 3–27
  8. Berchtold P, Muller D, Kouns WC, et al.  Plasma autoantibodies against platelet glycoprotein IIb/IIIa from patients with autoimmune thrombocytopenic purpura may recognize different antigenic determinants. Eur J Hematol. 1998;61:223–228
  9. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: Their clinical significance and response to treatment. Blood. 1993;81:1246–1250
  10. Bougie D, Visentin GP, Aster RH. A glucuronide acid conjugate of naproxen as a cause of drug-induced immune thrombocytopenia. Blood. 1995;86(suppl 1):1101; abstr
  11. Bougie D, Johnson ST, Weitekamp LA, et al.  Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood. 1997;90:407–413
  12. Chong BH, Du XP, Berndt MC, et al.  Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for quinine/quinidine-dependent antibodies. Blood. 1991;77:2190–2199
  13. Christie DJ, Müllen PC, Aster RH. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest. 1985;75:310–314
  14. Coleman JW. Protein haptenation by drugs. Clin Exp Allergy. 1998;28:79–82
  15. Curtis BR, McFarland JG, Wu GG, et al.  Antibodies associated with sulfonamide-induced immune thrombocytopenia react preferentially with calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood. 1994;84:176–183
  16. Escher R, Muller D, Vogel M, et al.  Recombinant human natural autoantibodies against GPIIb/IIIa inhibit binding of autoantibodies from patients with AITP. Br J Haematol. 1998;102:820–828
  17. Escher R, Wei Y, Amstutz P. Recombinant anti-GPIIb/IIIa autoantibodies from different normal donors share high homology. Blood. 1998;92(suppl 1):472a; abstr
  18. Filion MC, Bradley AJ, Devine DV, et al.  Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal allergy. Eur J Immunol. 1995;25:3123–3127
  19. Flavell RA, Hafler DA. Autoimmunity. What is the turning point?. Curr Opin Immunol. 1999;11:635–637
  20. Fujisawa K, Tani P, McMillan R. Platelet-associated antibody to glycoprotein IIb/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cationdependent antigens. Blood. 1993;81:1284–1289
  21. Garratty G. Target antigens for red-cell-bound autoantibodies. In:  Nance ST editors. Clinical and Basic Science Aspects of Immunohematology. Arlington, VA: American Association of Blood Banks; 1991;p. 33–72
  22. Garratty G. Immune cytopenia associated with antibiotics. Transfus Med Rev. 1993;7:255–267
  23. George JN, Raskob GE. Idiopathic thrombocytopenic purpura: A concise summary of the pathophysiology and the diagnosis in children and adults. In: ed 5. Semin Hematol. 35:1998;p. 5–8
  24. Gianani R, Sarvetnick N. Viruses, cytokines, antigens, and autoimmunity. In: ed 5. Proc Nad Acad Sci USA. 93:1996;p. 2257–2259
  25. Griem P, Gleichmann E. Metal ion induced autoimmunity. Curr Opin Immunol. 1995;7:831–838
  26. Griem P, Panthel K, Kalbacher H, et al.  Alteration of a model antigen by Au (III) leads to T cell sensitization to cryptic peptides. Eur J Immunol. 1996;26:279–287
  27. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342–349
  28. Kenna JG, Satoh H, Christ DD, et al.  Metabolic basis for a drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther. 1988;245:1103–1109
  29. Kiefel V, Freitag E, Kroll H, et al.  Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol. 1995;72:280–285
  30. Kosugi S, Tomiyama Y, Shiraga M, et al.  Platelet-associated anti-glycoprotein (GP) IIb/IIIa autoantibodies in chronic immune thrombocytopenic purpura mainly recognize cationdependent confirmations: Comparison with the epitopes of serum autoantibodies. Thromb Haemost. 1996;75:339–345
  31. Kuwana M, Kabuaraki J, Ikeda Y. Autoreactive T cells to platelet GPIIb/IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998;102:1393–1402
  32. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity?. J Exp Med. 1995;181:1945–1948
  33. Lerner W, Caruso R, Faig D, et al.  Drug-dependent and non-drug-dependent antiplatelet antibody in drug-induced immunologic thrombocytopenic purpura. Blood. 1985;66:306–311
  34. Lusher JM, Iyer R. Idiopathic thrombocytopenic purpura in children. In: ed 5. Semin Thromb Hemost. 3:1977;p. 175–199
  35. Merk HF, Baron J, Kawakubo Y, et al.  Metabolites and allergic drug reactions. Clin Exp Allergy. 1998;28:21–24
  36. Nieminen U, Kekomaki R. Quinidine-induced thrombocytopenic purpura: Clinical presentation in relation to drugdependent and drug-independent platelet antibodies. Br J Haematol. 1992;80:77–82
  37. Park BK, Kitteringham NR. Drug-protein conjugation and its immunological consequences. Drug Metab Rev. 1990;22:87–144
  38. Petz LD. Drug-induced autoimmune hemolytic anemia. Transfus Med Rev. 1993;7:242–254
  39. Pohl R, Sato HH, Christ DD, et al.  The immunologic and metabolic basis of drug hypersensitivities. Ann Rev Pharmacol. 1988;28:367–387
  40. Rizvi MA, Shah SR, Raskob GE, et al.  Drug-induced thrombocytopenia. Curr Opin Hematol. 1999;6:349–353
  41. Salamon DJ, Nusbacher J, Stroup ET, et al.  Red cell and platelet-bound IgG penicillin antibodies in a patient with thrombocytopenia. Transfusion. 1984;24:395–398
  42. Sercarz EE, Lahmann PV, Amatani A, et al.  Dominance and crypticity of T cell antigenic determinants. Ann Rev Immunol. 1993;11:729–766
  43. Sercarz EE, Mitchison NA. Autoimmunity. Immunologist. 1999;7:49–50
  44. Sercarz EE. Immune focusing vs diversification and their connection to immune regulation. Immunol Rev. 1998;164:5–10
  45. Shulman NR, Reid DM. Mechanisms of drug-induced immunologically mediated cytopenias. Transfus Med Rev. 1993;7:215–229
  46. Smith ME, Reid DM, Jones CE. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest. 1987;79:912–917
  47. Stroncek DF. Drug-induced immune neutropenia. Transfus Med Rev. 1993;7:268–274
  48. Szadtowski NS, Aster RH. Idiopathic (autoimmune) thrombocytopenic purpura with a complement-fixing autoantibody and response to plasma exchange. Scand J Haematol. 1985;35:525–530
  49. van der Lugt CL, Begolka WS, Neville KL, et al.  The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev. 1998;164:63–72
  50. van Pelt FNAM, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. In: ed 5. Semin Liver Dis. 15:1995;p. 283–300
  51. van der Weerdt CM. Veenhoven-von Riesz LE: Thrombocytopenia due to quinidine or quinine. Vox Sang. 1967;12:265–272
  52. Visentin GP, Newman PJ, Aster RH. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood. 1991;77:2668–2676
  53. Visentin GP, Wolfmeyer K, Newman PJ, et al.  Detection of drug-dependent, platelet-reactive antibodies by antigen capture ELISA and flow cytometry. Transfusion. 1990;30:694–700
  54. von dem Borne AEGKr, Pegels JG, van der Stadt RJ, et al.  Thrombocytopenia associated with gold therapy: A druginduced autoimmune disease?. Br J Haematol. 1986;63:509–516
  55. von Greyerz S, Zanni M, Schnyder B, Pichler WJ. Presentation of non-peptide antigens, in particular drugs, to specific T cells. Clin Exp Allergy. 1998;28:7–11
  56. Warkentin TE, Kelton JG. Current concepts in the treatment of immune thrombocytopenia. Drugs. 1990;40:531–542
  57. Weigle WO. The antibody response in rabbits to previously tolerated antigens. Ann NY Acad Sci. 1965;124:133–142
  58. Williams AM, Dickinson RG. Studies on the reactivity of acyl glucuronides. VI. Modulation of reversible and covalent interaction of diflunisal acyl glucuronide and its isomers with human plasma protein in vitro. Biochem Pharmacol. 1994;47:457–467
  59. Worlledge SM. Immune drug-induced hemolytic anemias. In: ed 5. Semin Haematol. 4:1973;p. 327–344
  60. Wormhoudt LW, Commandeur JN, Vermeulan NP. Genetic polymorphisms of human N-acetylase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase: Relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol. 1999;29:59–124
  61. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell. 1995;80:695–705
  62. Zia-Amirhosseini P, Spahn-Langguth H, Benet LZ. Bioactivity by glucuronide-conjugate formation. Adv Pharmacol. 1994;27:385–397
  63. Zia-Amirhosseini P, Harris RZ, Brodsky FM, et al.  Hypersensitivity to nonsteroidal antiinflammatory drugs. Nat Med. 1995;1:2–4

☆ Supported in part by Grants No. HL-13629 and HL-44612 from the National Heart, Lung, and Blood Institute.

PII: S0037-1963(00)90101-X

Seminars in Hematology
Volume 37, Issue 3 , Pages 229-238 , July 2000

Article Tools